Lack of prognostic value of CTNNB1 mutation ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis.
Auteur(s) :
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Bonvalot, Sylvie [Auteur]
Institut Curie [Paris]
Bimbai, André-Michel [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Meurgey, Alexandra [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Le Loarer, François [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Salas, Sébastien [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Marseille medical genetics - Centre de génétique médicale de Marseille [MMG]
Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique [COMPO]
Piperno-Neumann, Sophie [Auteur]
Institut Curie [Paris]
Chevreau, Christine [Auteur]
Institut Claudius Regaud
Boudou-Rouquette, Pascaline [Auteur]
Hôpital Cochin [AP-HP]
Dubray-Longeras, Pascale [Auteur]
Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP]
Kurtz, Jean-Emmanuel [Auteur]
Guillemet, Cécile [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
Bompas, Emmanuelle [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Italiano, Antoine [Auteur]
Institut de signalisation, biologie du développement et cancer - Institute of Developmental Biology and Cancer [IBDC]
Le Cesne, Axel [Auteur]
Institut Gustave Roussy [IGR]
Orbach, Daniel [Auteur]
Institut Curie [Paris]
Thery, Julien [Auteur]
Centre d'Etudes Médiévales de Montpellier [CEMM]
Le Deley, Marie Cecile [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Institut Gustave Roussy [IGR]
Blay, Jean-Yves [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Mir, Olivier [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Bonvalot, Sylvie [Auteur]
Institut Curie [Paris]
Bimbai, André-Michel [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Meurgey, Alexandra [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Le Loarer, François [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Salas, Sébastien [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Marseille medical genetics - Centre de génétique médicale de Marseille [MMG]
Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique [COMPO]
Piperno-Neumann, Sophie [Auteur]
Institut Curie [Paris]
Chevreau, Christine [Auteur]
Institut Claudius Regaud
Boudou-Rouquette, Pascaline [Auteur]
Hôpital Cochin [AP-HP]
Dubray-Longeras, Pascale [Auteur]
Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP]
Kurtz, Jean-Emmanuel [Auteur]
Guillemet, Cécile [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
Bompas, Emmanuelle [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Italiano, Antoine [Auteur]
Institut de signalisation, biologie du développement et cancer - Institute of Developmental Biology and Cancer [IBDC]
Le Cesne, Axel [Auteur]
Institut Gustave Roussy [IGR]
Orbach, Daniel [Auteur]
Institut Curie [Paris]
Thery, Julien [Auteur]
Centre d'Etudes Médiévales de Montpellier [CEMM]
Le Deley, Marie Cecile [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Institut Gustave Roussy [IGR]
Blay, Jean-Yves [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Mir, Olivier [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Titre de la revue :
Clinical Cancer Research
Nom court de la revue :
Clin Cancer Res
Date de publication :
2022-03-18
ISSN :
1557-3265
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Abstract Purpose: This prospective nationwide cohort study aimed to investigate desmoid-type fibromatosis (DF) outcomes, focusing on the prognostic value of CTNNB1 mutations. Experimental Design: ALTITUDES (NCT02867033) ...
Lire la suite >Abstract Purpose: This prospective nationwide cohort study aimed to investigate desmoid-type fibromatosis (DF) outcomes, focusing on the prognostic value of CTNNB1 mutations. Experimental Design: ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020. At diagnosis, CTNNB1 molecular alterations were identified using next-generation sequencing or Sanger sequencing. The primary endpoint was event-free survival (EFS; progression, relapse, or death). We enrolled 628 patients managed by active surveillance, surgical resection, or systemic treatment as first-line therapy. Results: Overall, 516 (82.2%) patients [368 females (71.3%), median age 40.3 years (range, 1–89)] were eligible for analysis. In 435 (84.3%) cases, there was one CTNNB1 molecular alteration: p.T41A, p.S45F, or p.S45P. The first-line management was active surveillance in 352 (68.2%), surgical resection in 120 (23.3%), and systemic treatments in 44 (8.5%) patients. CTNNB1 mutation distribution was similar across the three therapeutic groups. The median follow-up period was 24.7 (range, 0.4–59.7) months. The estimated 3-year EFS rate was 66.2% [95% confidence interval (CI), 60.5%–71.2%]. DF harboring p.S45F was significantly associated with male sex (P = 0.03), non-abdominal wall sites (P = 0.05), pain (P = 0.007), and large tumor size (P = 0.025). CTNNB1 p.S45F mutation was not significantly associated with EFS, either in univariate (HR, 1.06; 95% CI, 0.65–1.73; P = 0.81) or in multivariate analysis (HR, 0.91; 95% CI, 0.55–1.49; P = 0.71). Conclusions: We found that CTNNB1 mutation profile was associated with unfavorable prognostic factors but was not a prognostic factor for EFS. See related commentary by Greene and Van Tine, p. 3911Lire moins >
Lire la suite >Abstract Purpose: This prospective nationwide cohort study aimed to investigate desmoid-type fibromatosis (DF) outcomes, focusing on the prognostic value of CTNNB1 mutations. Experimental Design: ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020. At diagnosis, CTNNB1 molecular alterations were identified using next-generation sequencing or Sanger sequencing. The primary endpoint was event-free survival (EFS; progression, relapse, or death). We enrolled 628 patients managed by active surveillance, surgical resection, or systemic treatment as first-line therapy. Results: Overall, 516 (82.2%) patients [368 females (71.3%), median age 40.3 years (range, 1–89)] were eligible for analysis. In 435 (84.3%) cases, there was one CTNNB1 molecular alteration: p.T41A, p.S45F, or p.S45P. The first-line management was active surveillance in 352 (68.2%), surgical resection in 120 (23.3%), and systemic treatments in 44 (8.5%) patients. CTNNB1 mutation distribution was similar across the three therapeutic groups. The median follow-up period was 24.7 (range, 0.4–59.7) months. The estimated 3-year EFS rate was 66.2% [95% confidence interval (CI), 60.5%–71.2%]. DF harboring p.S45F was significantly associated with male sex (P = 0.03), non-abdominal wall sites (P = 0.05), pain (P = 0.007), and large tumor size (P = 0.025). CTNNB1 p.S45F mutation was not significantly associated with EFS, either in univariate (HR, 1.06; 95% CI, 0.65–1.73; P = 0.81) or in multivariate analysis (HR, 0.91; 95% CI, 0.55–1.49; P = 0.71). Conclusions: We found that CTNNB1 mutation profile was associated with unfavorable prognostic factors but was not a prognostic factor for EFS. See related commentary by Greene and Van Tine, p. 3911Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Date de dépôt :
2023-11-15T04:27:53Z
2024-01-09T12:36:57Z
2024-01-09T12:36:57Z